Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy

Hiroshima Journal of Medical Sciences

Volumn 60, Issue 1, 2011, Pages 7-9

  Nagao, Saeko ^a   Hattori, Noboru ^a   Fujitaka, Kazunori ^a   Iwamoto, Hiroshi ^a   Ohshimo, Shinichiro ^a   Kanehara, Masashi ^a   Ishikawa, Nobuhisa ^a   Haruta, Yoshinori ^a   Murai, Hiroshi ^a   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Anti tumor effect; Bone metastasis; Lung cancer; Zoledronic acid

Indexed keywords

CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADRENAL METASTASIS; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PATIENT; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LEG PAIN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPHADENOPATHY; POSITRON EMISSION TOMOGRAPHY; THORAX RADIOGRAPHY; ADENOCARCINOMA; BONE TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; TUMOR REGRESSION;

ADENOCARCINOMA; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM REGRESSION, SPONTANEOUS;

EID: 79959806347     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bäckman, U., Svensson, A., Christofferson, R.H. and Azarbayjani, F. 2008. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res. 28: 1551-1557. (Pubitemid 351892928)
2. Giraudo, E., Inoue, M. and Hanahan, D. 2004. An amino-bis-phosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114: 623-633.
3. Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., Samonigg, H., Tausch, C., Eidtmann, H., Steger, G., Kwasny, W., Dubsky, P., Fridrik, M., Fitzal, F., Stierer, M., Rücklinger, E. and Greil, R. 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360: 679-691.
4. Horino, T., Takao, T., Yamamoto, M., Geshi, T. and Hashimoto, K. 2006. Spontaneous remission of small cell lung cancer: a case report and review in the literature. Lung Cancer 53: 249-252. (Pubitemid 43994233)
5. Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J.F., Seaman, J. and Knight, R.D. 1996. Efficacy of Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335: 1785-1791.
6. Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y. and Takashima, S. 2005. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol. 23: 3314-3321.
7. Koto, K., Horie, N., Kimura, S., Murata, H., Sakabe, T., Matsui, T., Watanabe, M., Adachi, S., Maekawa, T., Fushiki, S. and Kubo, T. 2009. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett. 18: 271-278.
8. Märten, A., Lilienfeld-Toal, M., Büchler, M.W. and Schmidt, J. 2007. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J. Immunother. 30: 370-377. (Pubitemid 46684427)
9. Matsumoto, S., Kimura, S., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Nogawa, M., Tanaka, F., Maekawa, T. and Wada, H. 2005. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47: 31-39. (Pubitemid 39643239)
10. Miwa, S., Mizokami, A., Keller, E.T., Taichman, R., Zhang, J. and Namiki, M. 2005. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res. 65: 8818-8825. (Pubitemid 41377370)
11. Miwa, S., Mizokami, A., Konaka, H., Izumi, K., Nohara, T. and Namiki, M. 2009. A case of bone, lung, pleural and liver metastasis from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. Jpn. J. Clin. Oncol. 39: 745-750.
12. Okamoto, K., Tsurutani, J., Terashima, M., Okamoto, I. and Nakagawa, K. 2009. Zoledronic acid-induced regression of multiple metastases at nonskeletal sites. Ann. Oncol. 20: 796-797.
13. Roodman, G.D. 2004. Mechanism of bone metastasis. N. Engl. J. Med. 350: 1655-1664.
14. Rosen, L.S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., Reitsma, D. and Seaman, J.J. 2003. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the zoledronic acid lung cancer and other solid tumors study group. J. Clin. Oncol. 21: 3150-3157.